Corcept Therapeutics 3Q 2026: Revenue $340.47M, Net income $124.49M, EPS $1.01— 10-Q Summary

What happened

Corcept Therapeutics reported third-quarter 2026 revenue of $340.47 million, up 64% from a year earlier. Net income was $124.49 million and diluted earnings per share were $1.01. Lifyorli, launched in the U.S. in April 2026, generated $91.4 million in quarterly revenue.

Confirmed

Global impact / market context

The results show Corcept's earnings power widening well beyond its older hypercortisolism products, because Lifyorli contributed $91.4 million in its first full sales quarter. Faster profit growth than revenue growth means more of each sales dollar reaches the bottom line, which supports cash available for drug trials.

Analyst inference

Investors are weighing a fast-growing product launch against regulatory risk. Corcept resubmitted its hypercortisolism new drug application, which is a formal approval request, after FDA-requested analyses, with a decision targeted for December 17, 2026. That pending decision, plus a distribution partner switch to Curant, shapes how durable investors view the growth.

Analyst inference

What to watch

1. The FDA decision on Corcept's resubmitted hypercortisolism new drug application is targeted for December 17, 2026, so the outcome could change expected revenue from that franchise. Confirmed
2. Watch whether Lifyorli sales hold near the $91.4 million third-quarter level, because a second strong quarter would suggest the launch is building rather than one-time stocking. Proposed
3. Track whether research and development spending stays roughly flat year over year as oncology trials advance, since controlled costs would help profit per sale hold up. Analyst inference

Evidence

• Original source link unavailable